Featured Jobs
|
July Business Services
|
|
Strongpoint Partners
|
|
Anchor 3(16) Fiduciary Solutions
|
|
Retirement Plan Consultants
|
|
EPIC RPS
|
|
Managing Director - Operations, Benefits Daybright Financial
|
|
ESOP Administration Consultant Blue Ridge Associates
|
|
Nova 401(k) Associates
|
|
Combo Retirement Plan Administrator Strongpoint Partners
|
|
Cash Balance/ Defined Benefit Plan Administrator Steidle Pension Solutions, LLC
|
|
Mergers & Acquisition Specialist Compass
|
|
Retirement Plan Administration Consultant Blue Ridge Associates
|
|
MVP Plan Administrators, Inc.
|
|
Relationship Manager for Defined Benefit/Cash Balance Plans Daybright Financial
|
|
BPAS
|
|
DC Retirement Plan Administrator Michigan Pension & Actuarial Services, LLC
|
|
Compass
|
Free Newsletters
“BenefitsLink continues to be the most valuable resource we have at the firm.”
-- An attorney subscriber
|
|
|
| Webinars and Podcasts |
> | Upcoming | On-Demand |
| Conferences | > | Upcoming | Grouped by Location |
| All Webinars, Podcasts and Conferences | > | Upcoming | Grouped by Sponsor |
View More BARBRI Webinars, Podcasts and Conferences
Executive Orders Targeting Prescription Drug Prices: Agency Objectives, Healthcare Industry Impact, Compliance IssuesBARBRI |
|
Sept. 8, 2025 On-Demand Webinar |
|
This CLE webinar will examine two recently released executive orders (EOs) issued by the new administration related to prescription drug pricing and discuss how these may affect the healthcare industry and who may be most impacted. The panel will discuss the agency objectives outlined in each EO, address agency action to date, and provide best practices for helping healthcare clients navigate this rapidly changing regulatory environment. Description The Trump administration recently issued two executive orders aimed at lowering prescriptions drug prices and addressing drug pricing strategies—"Lowering Drug Prices by Once Again Putting Americans First" on Apr. 15, 2025 (April EO) and "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients" on May 12, 2025 (May EO). The April EO was the first significant action taken by the new administration to address drug prices in various areas, including pricing related to pharmacy benefit managers, Medicare and Medicaid, international importation, and competition in drug manufacturing. The May EO directed federal agencies to implement policies to tie prescription drug prices to international price targets and to facilitate direct to consumer sales at the most favored nation price. While each EO contains broad mandates to agencies, many questions as to how these will be accomplished are left unanswered, creating compliance challenges for those in the healthcare industry. Therefore, counsel should understand the EOs' objectives, agency impact and action taken to date to fulfill these objectives, and how healthcare clients may be affected in order to help them navigate this rapidly evolving regulatory landscape. Listen as our expert panel closely examines the EOs and how they reflect the administration's policy objectives related to prescription drug pricing. The panel will discuss related agency action and address how these may impact the healthcare industry. The panel will also offer best practices for compliance. |